Blood Pressure Pills May Halve Colon Surgery Risk
Blood Pressure Pills May Halve Colon Surgery Risk
Blood Pressure Pills May Halve Colon Surgery Risk
Key points
اہم نکات
मुख्य बातें
- Common blood pressure drugs may help some ulcerative colitis patients avoid surgery to remove their colon, a new study suggests.
- Researchers at Northwestern Medicine and Kiel University in Germany looked at more than 1,300 patients in two clinical trials of vedolizumab, a drug for ulcerative colitis, the most common form of inflammatory bowel disease.
- Patients who also took ACE inhibitors or ARBs for high blood pressure needed colon-removal surgery roughly half as often as similar patients who did not, and were less likely to be admitted to hospital.
- Common blood pressure drugs may help some ulcerative colitis patients avoid surgery to remove their colon, a new study suggests.
- Researchers at Northwestern Medicine and Kiel University in Germany looked at more than 1,300 patients in two clinical trials of vedolizumab, a drug for ulcerative colitis, the most common form of inflammatory bowel disease.
- Patients who also took ACE inhibitors or ARBs for high blood pressure needed colon-removal surgery roughly half as often as similar patients who did not, and were less likely to be admitted to hospital.
- Common blood pressure drugs may help some ulcerative colitis patients avoid surgery to remove their colon, a new study suggests.
- Researchers at Northwestern Medicine and Kiel University in Germany looked at more than 1,300 patients in two clinical trials of vedolizumab, a drug for ulcerative colitis, the most common form of inflammatory bowel disease.
- Patients who also took ACE inhibitors or ARBs for high blood pressure needed colon-removal surgery roughly half as often as similar patients who did not, and were less likely to be admitted to hospital.
Common blood pressure drugs may help some ulcerative colitis patients avoid surgery to remove their colon, a new study suggests. Researchers at Northwestern Medicine and Kiel University in Germany looked at more than 1,300 patients in two clinical trials of vedolizumab, a drug for ulcerative colitis, the most common form of inflammatory bowel disease. Patients who also took ACE inhibitors or ARBs for high blood pressure needed colon-removal surgery roughly half as often as similar patients who did not, and were less likely to be admitted to hospital. The benefit appeared only with vedolizumab and only with those two drug classes, not with beta blockers or calcium channel blockers. The findings, published on November 9 in Nature Medicine, come from medical records rather than a randomised trial, so the authors say dedicated trials are needed to confirm the effect.
Common blood pressure drugs may help some ulcerative colitis patients avoid surgery to remove their colon, a new study suggests. Researchers at Northwestern Medicine and Kiel University in Germany looked at more than 1,300 patients in two clinical trials of vedolizumab, a drug for ulcerative colitis, the most common form of inflammatory bowel disease. Patients who also took ACE inhibitors or ARBs for high blood pressure needed colon-removal surgery roughly half as often as similar patients who did not, and were less likely to be admitted to hospital. The benefit appeared only with vedolizumab and only with those two drug classes, not with beta blockers or calcium channel blockers. The findings, published on November 9 in Nature Medicine, come from medical records rather than a randomised trial, so the authors say dedicated trials are needed to confirm the effect.
Common blood pressure drugs may help some ulcerative colitis patients avoid surgery to remove their colon, a new study suggests. Researchers at Northwestern Medicine and Kiel University in Germany looked at more than 1,300 patients in two clinical trials of vedolizumab, a drug for ulcerative colitis, the most common form of inflammatory bowel disease. Patients who also took ACE inhibitors or ARBs for high blood pressure needed colon-removal surgery roughly half as often as similar patients who did not, and were less likely to be admitted to hospital. The benefit appeared only with vedolizumab and only with those two drug classes, not with beta blockers or calcium channel blockers. The findings, published on November 9 in Nature Medicine, come from medical records rather than a randomised trial, so the authors say dedicated trials are needed to confirm the effect.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।